Biblio

Author Title [ Type(Asc)] Year
Filters: Author is He, Yang  [Clear All Filters]
Journal Article
Wen J, Liu L, Li J, He Y. A review of nardosinone for pharmacological activities. Eur J Pharmacol. 2021:174343.
Huang F, He Y, Zhang M, Luo K, Li J, Li J, Zhang X, Dong X, Tang J. Progress in Research on Stem Cells in Neonatal Refractory Diseases. J Pers Med. 2023;13(8).
Yin S, Yu Y, Wu N, Zhuo M, Wang Y, Niu Y, Ni Y, Hu F, Ding C, Liu H, et al. Patient-derived tumor-like cell clusters for personalized chemo- and immunotherapies in non-small cell lung cancer. Cell Stem Cell. 2024.
He L, Zheng Y, Liu M, Dong X, Shen L, He Y, An J, Zhang Y. Nd:YAG-photobiomodulation enhanced ADSCs multilineage differentiation and immunomodulation potentials. Lasers Med Sci. 2023;38(1):190.
He Y, Tang J, Zhang M, Ying J, Mu D. Human placenta derived mesenchymal stem cells transplantation reducing cellular apoptosis in hypoxic-ischemic neonatal rats by down-regulating Semaphorin 3A/Neuropilin-1. Neuroscience. 2023.
Fang Y, Zhang M-C, He Y, Li C, Fang H, Xu P-P, Cheng S, Zhao Y, Feng Y, Liu Q, et al. Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8(1):381.
Zhao D, Zhao H, He Y, Zhang M. BMSC reduces ROS and inflammation levels by inhibiting TLR4/MYD88/NF-κB signaling axis to alleviate dry eye. Res Sq. 2023.
Zhao D, Zhao H, He Y, Zhang M. BMSC Alleviates Dry Eye by Inhibiting the ROS-NLRP3-IL-1β Signaling Axis by Reducing Inflammation Levels. Curr Eye Res. 2024:1-10.
Cao X-Y, Chen J-Q, Wang H, Ma W, Liu W-W, Zhang F-F, Xue S, Dong L, Liu T, Zhao X-Z, et al. Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML. Ann Med. 2023;55(1):388-400.